This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): Tacrolimus Inhalant
Description: FK506 is an inhaled formulation of tacrolimus. Tacrolimus forms a complex with a binding protein and blocks calcineurin. In T cells, this leads to blockage of IL-2 formation. IL-2 is required for full T-cell activation. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-a, which are involved in the early stages of T-cell activation.
FK506 (inhalant) News
Pink Sheet Fujisawa’s FK506
Additional information available to subscribers only: